Introduction: Metabolic dysfunction-associated steatotic liver disease (MASLD) is linked to increased cardiovascular (CV) risks, notably congestive heart failure (CHF). We evaluated the influence of MASLD on CHF and mortality among hospitalized cirrhotic patients.
Methods: We analyzed the National Inpatient Sample from 2016 to 2020, identifying adult cirrhosis patients.